AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
More News related to AEZS
- AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
- AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology
- Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
- Aeterna Zentaris (AEZS) Posts Q3 Loss of 19c, Beats by 2c
- AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results
More News related to KERX
- AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
- AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology
- Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
- Keryx Biopharma (KERX) Posts Q3 EPS of 1c, Beats by 10c
- Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
More News related to Corporate News
- Odyssey Marine (OMEX) Acquires Minority Stake in SMM Project LLC
- NASDAQ Grants Comstock Homebuilding (CHCI) Continued Listing Request
- Agilysys (AGYS) Announces Special Meeting of Shareholders to Vote on Proposed Control Share Acquisition by MAK Capital
- Highlights From SJM's Q2 Conference Call: Acquisition of Folger's Really Paying Off; Comfortable Raising FY Outlook
- Pfizer (PFE) Gets Okay for Bipolar Treatment Geodon from U.S. FDA
AEterna Zentaris Inc. (NASDAQ: AEZS) today announced that Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), its partner and licensee for perifosine (KRX-0401) in the North American market, will present data from a Phase 1/2 clinical trial of perifosine in combination with bortezomib (+/- dexamethasone), during a poster presentation session at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.
The clinical data to be presented demonstrates the potential safety and efficacy of perifosine in the treatment of patients with relapsed/refractory multiple myeloma.
Related Categories
Corporate NewsStocks Mentioned
+0.01
-0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
